DC-102
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-02806 |
| CAS | 115722-50-4 |
| Molecular Weight | 461.55 |
| Molecular Formula | C24H35N3O6 |
Online Inquiry
Description
DC-102 is produced by the strain of Streptomyces sp. It has anti-gram-positive bacteria activity and anti-tumor effect.
Specification
| Synonyms | DC 102 Antibiotic; 5H-Pyrrolo(2,1-c)(1,4)benzodiazepin-5-one, 1,2,3,10,11,11a-hexahydro-7-((4,6-dideoxy-3-C-methyl-4-(methylamino)-alpha-L-mannopyranosyl)oxy)-11-methoxy-2-propylidene- |
| IUPAC Name | (8E)-2-[(2S,3R,4R,5S,6S)-3,4-dihydroxy-4,6-dimethyl-5-(methylamino)oxan-2-yl]oxy-6-methoxy-8-propylidene-6,6a,7,9-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-one |
| Canonical SMILES | CCC=C1CC2C(NC3=C(C=C(C=C3)OC4C(C(C(C(O4)C)NC)(C)O)O)C(=O)N2C1)OC |
| InChI | InChI=1S/C24H35N3O6/c1-6-7-14-10-18-21(31-5)26-17-9-8-15(11-16(17)22(29)27(18)12-14)33-23-20(28)24(3,30)19(25-4)13(2)32-23/h7-9,11,13,18-21,23,25-26,28,30H,6,10,12H2,1-5H3/b14-7+/t13-,18?,19-,20-,21?,23-,24+/m0/s1 |
| InChI Key | MOZKTLDMJSXLBW-HXIFYCGYSA-N |
Properties
| Appearance | White Powder |
| Antibiotic Activity Spectrum | Gram-positive bacteria; neoplastics (Tumor) |
| Boiling Point | 674.5°C at 760 mmHg |
| Melting Point | 120°C |
| Density | 1.29 g/cm3 |
Reference Reading
1. [Chlorhexidine digluconate/chlorocresol combination. In vitro study of interactions observed against potential cutaneous strains]
C Roques, J Luc, D Toselli, G Michel Pathol Biol (Paris). 1993 Apr;41(4):358-63.
The interaction type of chlorhexidine digluconate/chlorocresol association (foaming solution DC 102/1, Laboratoires Pierre Fabre Médicament) have been studied according to the chess-board method, on microplate, by determining MBC (Minimal Bactericidal Concentrations) (or MFC (Minimal Fungicidal Concentrations)) adjusted to T 72-150 AFNOR norm (dilution-neutralization, contact 5 mn) and computation of FBC (or FFC) Index. Trials were carried out against 18 hospital strains (Staphylococcus epidermidis, Staphylococcus aureus, Propionibacterium acnes, Candida albicans) and against 4 strains of the AF-NOR norm. MBC of chlorhexidine, against Staphylococci were included between 6.25 and 25 micrograms/ml, and between 25 and 200 micrograms/ml against the others strains. MBC of chlorocresol were included between 800 and 3,200 micrograms/ml. Against the 22 tested strains, 18 synergistic interactions (FBC Index < or = 0.75) were observed, with 4 to 8 reducing factor for chlorhexidine, and > or = 2 for chlorocresol. No antagonism was noted (maximal FBC Index = 1).
2. Variation in oil content and fatty acid composition of the seed oil of Acacia species collected from the northwest zone of India
Riyazuddeen Khan, Ruchi Srivastava, Mather Ali Khan, Pravej Alam, Malik Zainul Abdin, Mahmooduzzafar J Sci Food Agric. 2012 Aug 30;92(11):2310-5. doi: 10.1002/jsfa.5627. Epub 2012 Feb 20.
Background: The oil content and fatty acid composition of the mature seeds of Acacia species collected from natural habitat of the northwest zone of the Indian subcontinent (Rajasthan) were analyzed in order to determine their potential for human or animal consumption. Results: Oil content varied between 40 and 102 g kg⁻¹. The highest oil content was obtained in Acacia bivenosa DC. (102 g kg⁻¹) among the nine Acacia species. The fatty acid composition showed higher levels of unsaturated fatty acids, especially linoleic acid (~757.7 g kg⁻¹ in A. bivenosa), oleic acid (~525.0 g kg⁻¹ in A. nubica) and dominant saturated fatty acids were found to be 192.5 g kg⁻¹ palmitic acid and 275.6 g kg⁻¹ stearic acid in A. leucophloea and A. nubica respectively. Seed oils of Acacia species can thus be classified in the linoleic-oleic acid group. Significant variations were observed in oil content and fatty acid composition of Acacia species. Conclusion: The present study revealed that the seed oil of Acacia species could be a new source of high linoleic-oleic acid-rich edible oil and its full potential should be exploited. The use of oil from Acacia seed is of potential economic benefit to the poor native population of the areas where it is cultivated. The fatty acid composition of Acacia seed oils is very similar to that reported for commercially available edible vegetable oils like soybean, mustard, sunflower, groundnut and olive. Hence the seed oil of Acacia species could be a new source of edible vegetable oil after toxicological studies.
3. Secretory Leukocyte Protease Inhibitor (SLPI)-A Novel Predictive Biomarker of Acute Kidney Injury after Cardiac Surgery: A Prospective Observational Study
Luisa Averdunk, Christina Fitzner, Tatjana Levkovich, David E Leaf, Michael Sobotta, Jil Vieten, Akinobu Ochi, Gilbert Moeckel, Gernot Marx, Christian Stoppe J Clin Med. 2019 Nov 9;8(11):1931. doi: 10.3390/jcm8111931.
Acute kidney injury (AKI) is one of the most frequent complications after cardiac surgery and is associated with poor outcomes. Biomarkers of AKI are crucial for the early diagnosis of this condition. Secretory leukocyte protease inhibitor (SLPI) is an alarm anti-protease that has been implicated in the pathogenesis of AKI but has not yet been studied as a diagnostic biomarker of AKI. Using two independent cohorts (development cohort (DC), n = 60; validation cohort (VC), n = 148), we investigated the performance of SLPI as a diagnostic marker of AKI after cardiac surgery. Serum and urinary levels of SLPI were quantified by ELISA. SLPI was significantly elevated in AKI patients compared with non-AKI patients (6 h, DC: 102.1 vs. 64.9 ng/mL, p < 0.001). The area under the receiver operating characteristic curve of serum SLPI 6 h after surgery was 0.87 ((0.76-0.97); DC). The addition of SLPI to standard clinical predictors significantly improved the predictive accuracy of AKI (24 h, VC: odds ratio (OR) = 3.91 (1.44-12.13)). In a subgroup, the increase in serum SLPI was evident before AKI was diagnosed on the basis of serum creatinine or urine output (24 h, VC: OR = 4.89 (1.54-19.92)). In this study, SLPI was identified as a novel candidate biomarker for the early diagnosis of AKI after cardiac surgery.
Recommended Products
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-03754 | CASTANOSPERMINE | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
